As our findings demonstrated a more potent reduction in the cell viability of multiple myeloma cells using propranolol compared with the selective β2AR‐blocker ICI‐118,551 (Figure 2A–F), we further elucidated the anti‐myeloma effects of the non‐selective β2AR‐blocker propranolol. This evidence concerns the gene ADRB2 and plasma cell myeloma.